| |
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| By Kevin Dunleavy Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. The company has handed pink slips to 195 more employees, according to a New Jersey Worker Adjustment and Retraining Notification update. |
|
|
|
By Fraiser Kansteiner Kronos will lay off some 83% of its workforce by the end of the year as it continues to explore options to stay afloat, including “possible business combinations” or the divesture of remaining preclinical assets. Additionally, the company's CEO, Norbert Bischofberger, Ph.D., is stepping down from his post on Dec. 3. |
By Fraiser Kansteiner President-elect Donald Trump has named Johns Hopkins surgeon and author Martin Makary, M.D., as his choice for FDA commissioner during his upcoming term. |
By Gabrielle Masson President-elect Donald Trump has chosen Stanford University’s Jay Bhattacharya, M.D., Ph.D., to serve as the director of the National Institutes of Health. |
|
Tuesday, December 10, 2024 | 11am ET / 8am PT This webinar brings together industry experts to explore the latest advancements in risk reduction and process optimization for ready-to-use fill/finish manufacturing. Register now.
|
|
By Kevin Dunleavy The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona and is evaluating the need for “further regulatory action,” the U.S. agency said last week. The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 children who received Skysona during clinical trials had developed blood cancer. |
By Nick Paul Taylor Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, which Roche has said can democratize CAR-Ts, as a new core capability at the drugmaker. |
By Ben Adams Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with megablockbuster sales in a market that could be worth $126 billion by 2030 just on the horizon. |
By Conor Hale The company’s wearable therapy improved overall survival as part of a first-line regimen for patients with inoperable pancreatic adenocarcinoma, one of the most lethal cancers. |
By Joseph Keenan Indian drugmaker Lupin is recalling more than 600,000 bottles of the high blood pressure and heart failure drug ramipril due to the presence of an active pharmaceutical ingredient (API) that came from an unapproved vendor. |
By Darren Incorvaia Proliferative vitreoretinopathy is an eye condition that leads to blindness and can currently only be addressed with surgery. A team led by research hospital Massachusetts Eye and Ear and German biotech CureVac has designed an mRNA therapy that delivered a therapeutic gene transcript to the eyes of rabbits with the disease, reducing the harmful excess of scar tissue that is characteristic of the condition. |
| | This week on "Podnosis," Rachel Harrington, Ph.D., AVP of health equity sciences at NCQA, discusses advancing health equity, data challenges and 2025 updates to HEDIS measures. |
|
|---|
|
|
|
Wednesday, December 11, 2024 | 2pm ET / 11am PT As pharma manufacturers adapt to a rapidly evolving landscape of patient support, the choice to build, buy, or borrow hub services is more critical than ever. Join industry experts to explore key trends driving the hybrid hub model and gain actionable insights on how to balance in-house control with outsourced efficiency. Register now.
|
|
| SurveyExplore the latest trends in compliance monitoring to help your team embrace proactive strategies in key areas of risk management. Stay ahead of the ever-evolving landscape and new policies to enhance your compliance program. Sponsored by: IQVIA |
| ResearchRead this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Selecting a 3PL with a proven track record of delivering high-quality services is critical to a successful pharma supply chain. Here's how. Sponsored by: BioCare |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
